278 related articles for article (PubMed ID: 12597338)
41. The anti-diabetic bis(maltolato)oxovanadium(IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains.
Winter PW; Al-Qatati A; Wolf-Ringwall AL; Schoeberl S; Chatterjee PB; Barisas BG; Roess DA; Crans DC
Dalton Trans; 2012 Jun; 41(21):6419-30. PubMed ID: 22569684
[TBL] [Abstract][Full Text] [Related]
42. Effects of bis(maltolato) oxovanadium (IV) on protein serine kinases in skeletal muscle of streptozotocin-diabetic rats.
Bhanot S; Girn J; Poucheret P; McNeill JH
Mol Cell Biochem; 1999 Dec; 202(1-2):131-40. PubMed ID: 10706003
[TBL] [Abstract][Full Text] [Related]
43. Cytoprotective effect of 16,16' dimethyl prostaglandin E2 (dm PGE2) on streptozotocin-induced biochemical alterations of Golgi-rich membrane fraction in comparison with morphology of rat liver Golgi apparatus in situ.
Kordowiak AM
Pathol Res Pract; 1986 Aug; 181(4):397-401. PubMed ID: 2945173
[TBL] [Abstract][Full Text] [Related]
44. Insulin-like effects of bis-glycinato oxovanadium (IV) complex on experimental diabetic rats.
Nandhini D; Maneemegalai S; Elangovan V; Sekar N; Govindasamy S
Indian J Biochem Biophys; 1993 Feb; 30(1):73-6. PubMed ID: 8509129
[TBL] [Abstract][Full Text] [Related]
45. Aqueous chemistry of the vanadium(III) (V(III)) and the V(III)-dipicolinate systems and a comparison of the effect of three oxidation states of vanadium compounds on diabetic hyperglycemia in rats.
Buglyó P; Crans DC; Nagy EM; Lindo RL; Yang L; Smee JJ; Jin W; Chi LH; Godzala Iii ME; Willsky GR
Inorg Chem; 2005 Jul; 44(15):5416-27. PubMed ID: 16022540
[TBL] [Abstract][Full Text] [Related]
46. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on non-diabetic and streptozotocin-diabetic rats.
Gao LH; Liu WP; Wang BL; Li L; Xie MJ; Li YR; Chen ZH; Chen XZ
Clin Chim Acta; 2006 Jun; 368(1-2):173-8. PubMed ID: 16487949
[TBL] [Abstract][Full Text] [Related]
47. Morphology of the Golgi apparatus in streptozotocin-diabetic rat liver.
Sarnecka-Keller M; Kaczmarski F; Kordowiak A
Pathol Res Pract; 1980; 168(1-3):126-33. PubMed ID: 6448994
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of protein tyrosin phosphatase improves vascular endothelial dysfunction.
Shah DI; Singh M
Vascul Pharmacol; 2006 Mar; 44(3):177-82. PubMed ID: 16442349
[TBL] [Abstract][Full Text] [Related]
49. New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.
Liboiron BD; Thompson KH; Hanson GR; Lam E; Aebischer N; Orvig C
J Am Chem Soc; 2005 Apr; 127(14):5104-15. PubMed ID: 15810845
[TBL] [Abstract][Full Text] [Related]
50. Protective effect of caffeic acid phenethyl ester (CAPE) on lipid peroxidation and antioxidant enzymes in diabetic rat liver.
Yilmaz HR; Uz E; Yucel N; Altuntas I; Ozcelik N
J Biochem Mol Toxicol; 2004; 18(4):234-8. PubMed ID: 15452882
[TBL] [Abstract][Full Text] [Related]
51. Influence of sodium bis(oxalato)oxovanadate(IV) on phospholipids in liver Golgi fractions from control and streptozotocin-diabetic rats.
Kordowiak AM; Dudek B; Gryboś R
Comp Biochem Physiol C Toxicol Pharmacol; 2000 Jan; 125(1):11-6. PubMed ID: 11790325
[TBL] [Abstract][Full Text] [Related]
52. Hypoglycemic effect of macrocyclic binuclear oxovanadium (IV) complex on streptozotocin-induced diabetic rats.
Ramachandran B; Sekar DS; Kandaswamy M; Narayanan V; Subramanian S
Exp Diabesity Res; 2004; 5(2):137-42. PubMed ID: 15203884
[TBL] [Abstract][Full Text] [Related]
53. Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats.
Jindal S; Singh M; Balakumar P
Int J Cardiol; 2008 Aug; 128(3):383-91. PubMed ID: 17658639
[TBL] [Abstract][Full Text] [Related]
54. Bis(maltolato)oxovanadium(IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats.
Bhanot S; Bryer-Ash M; Cheung A; McNeill JH
Diabetes; 1994 Jul; 43(7):857-61. PubMed ID: 8013747
[TBL] [Abstract][Full Text] [Related]
55. The tyrosine phosphatase inhibitor bis(maltolato)oxovanadium attenuates myocardial reperfusion injury by opening ATP-sensitive potassium channels.
Liem DA; Gho CC; Gho BC; Kazim S; Manintveld OC; Verdouw PD; Duncker DJ
J Pharmacol Exp Ther; 2004 Jun; 309(3):1256-62. PubMed ID: 14993257
[TBL] [Abstract][Full Text] [Related]
56. Influence of chelation and oxidation state on vanadium bioavailability, and their effects on tissue concentrations of zinc, copper, and iron.
Thompson KH; Tsukada Y; Xu Z; Battell M; McNeill JH; Orvig C
Biol Trace Elem Res; 2002 Apr; 86(1):31-44. PubMed ID: 12002658
[TBL] [Abstract][Full Text] [Related]
57. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
58. Insulin-induced immunohistochemical and morphological changes in pancreatic beta-cells of streptozotocin-treated diabetic rats.
Adewole SO; Ojewole JA
Methods Find Exp Clin Pharmacol; 2007 Sep; 29(7):447-55. PubMed ID: 17982509
[TBL] [Abstract][Full Text] [Related]
59. Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin.
Bordbar AK; Creagh AL; Mohammadi F; Haynes CA; Orvig C
J Inorg Biochem; 2009 Apr; 103(4):643-7. PubMed ID: 19056126
[TBL] [Abstract][Full Text] [Related]
60. Changes in iron metabolism and oxidative status in STZ-induced diabetic rats treated with bis(maltolato) oxovanadium (IV) as an antidiabetic agent.
Sánchez-González C; López-Chaves C; Trenzado CE; Aranda P; López-Jurado M; Gómez-Aracena J; Montes-Bayón M; Sanz-Medel A; Llopis J
ScientificWorldJournal; 2014; 2014():706074. PubMed ID: 24511298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
